中国医药科学Issue(13)：14-17,4.
替吉奥联合奥沙利铂与卡培他滨联合奥沙利铂一线治疗老年晚期胃癌的疗效分析
Effects of oteracil or capecitabine combined with oxaliplatin as first-line treatment in elderly patients with advanced gastric cancer
刘福银 1孟丽娟 1王峻 1杨民 1樊卫飞1
作者信息
- 1. 江苏省老年医学研究所肿瘤内科，江苏南京210024
- 折叠
摘要
Abstract
Objective To compare the activity and safety of oteracil or capecitabine combined with oxaliplatin as first line therapy to treat elderly advanced gastric cancer(AGC)patients. Methods 56 elderly patients with pathologically diagnosed as advanced gastric cancer were randomly divided into a treatment group of 30 patients and a control group of 26 patients. Treatment group were given oteracil combined with oxaliplatin, while the control group were given capecitabine and oxaliplatin. The patients received oteracil at 40 mg [body surface area (BSA) <1.25 m2] or 50 mg twice a day for 14 days, followed by a 7-day rest period within a 3-week schedule in the therapy group, and capecitabine at 1000 mg/m2 twice a day for 14 days, followed by a 7-day rest period within a 3-week schedule in the control group. Oxaliplatin 85 mg/m2 were administered on d1 every 3 weeks in both groups. Treatment was continued until disease progression or the development unacceptable toxicity. Results The therapy group were observed a response rate (RR) of 40%, a tumor growth control rate (TGCR) of 57.3%, a median progression-free-time (PFS) of 6.0 months and a median overal survival(OS) of 11.5 months. While the control group were observed a RR of 44%, a TGCR of 59.7%, a median PFS of 6.3 months and a median OS of 11.9 months. There were no significant differences in activity. In two groups, quality of life was improved and there were no significant differences between groups. The treatment was well tolerated. The most frequent grade 3 or 4 toxicities were thrombocytopenia (16.6%) for therapy group and neutropenia (19.2%) for control group. No neutropenic fever occurred. No treatment-related deaths occurred during the research period. Conclusion Oteracil or capecitabine combined with oxaliplatin regimens in elderly patients with untreated AGC are effective. The treatment is well tolerated. The comparison of oteracil with capecitabine showed that capecitabine has a slightly higher response rate.关键词
替吉奥/卡培他滨/老年晚期胃癌Key words
Oteracil/Capecitabine/Elderly patients with advanced gastric cancer分类
医药卫生引用本文复制引用
刘福银,孟丽娟,王峻,杨民,樊卫飞..替吉奥联合奥沙利铂与卡培他滨联合奥沙利铂一线治疗老年晚期胃癌的疗效分析[J].中国医药科学,2013,(13):14-17,4.
